Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone

This retrospective database study analyzed resource utilization and costs associated with sitagliptin (STG) in comparison with rosiglitazone (RSG) added to metformin (MET) monotherapy among adults with a diagnosis of diabetes who were continuously enrolled in a large US healthcare plan.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Continuously enrolled in the health insurance plan to ensure complete claims coverage
At least 1 claim with a diagnosis of diabetes (ICD-9 250.xx)
Aged 18 years or older at the index date
At least 6 months of baseline period prior to the index date
At least 1 claim for MET during the baseline period
At least 180 days of continuous therapy with RSG+MET or STG+MET after the index date

Exclusion criteria

At least 1 claim for insulin or sulfonylurea in the baseline period
At least 1 claim with a diagnosis of congestive heart failure in the baseline period

Treatment and study plan

Rosiglitazone + Metformin

Drug

At least 180 days of continuous therapy with RSG+MET after the first Rx for RSG

Other names: Avandia(TM)

Sitagliptin + Metformin

Drug

At least 180 days of continuous therapy with STG+MET after the first Rx for STG

Other names: Januvia(R)

Primary outcomes

medical resource utilization

Time frame: at least 12 months following first prescription with RSG or STG as an add-on therapy to MET monotherapy.

Direct healthcare and indirect sick leave costs

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Important dates

Study start: 2009
Primary completion: 2010
Study completion: 2010
First posted: Apr 11, 2011
Registry last updated: Jun 2, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed